HOME >> MEDICINE >> NEWS
Studies suggest investigational agent reduces disease activity in MS

BOSTON A new drug under investigation shows a reduction in disease activity in multiple sclerosis (MS), according to two studies that will be presented at the American Academy of Neurology's 59th Annual Meeting in Boston, April 28 May 5, 2007. The drug reduced disease activity as indicated by MRI scans.

Both of the studies involved people with the relapsing-remitting form of MS, where symptoms flare up and then subside. By 24 weeks, treatment with the drug rituximab reduced the number of areas of brain damage, or lesions, in people with MS and the number of relapses, or times when symptoms flare up, when compared with placebo.

Rituximab is a therapeutic antibody that selectively targets and depletes a subset of immune cells called B-cells by targeting a specific protein on their surface.

"This is the first drug to target B-cells and may represent a potential new treatment strategy for relapsing-remitting MS," said study author Stephen Hauser, MD, of the University of California, San Francisco, and a member of the American Academy of Neurology. "While these are early stage clinical trials, these results are exciting, because the current drugs available for MS are only partially effective in reducing disease activity and preventing exacerbations. New and more effective treatments for MS are sorely needed, especially for people who do not adequately respond to currently available medications. These data are also important because they demonstrate that B-cells, which are the precursors of antibody-producing cells, play an essential role in mediating relapses of MS."

In the first study, a randomized, placebo-controlled trial, 69 people were given two infusions of rituximab two weeks apart and 35 were given a placebo. The participants were followed for six months. Those given rituximab had approximately 90 percent fewer brain lesions than those given placebo. During the six-month period, 58 percent fewer of those taking the d
'"/>

Contact: Angela Babb
ababb@aan.com
651-695-2789
American Academy of Neurology
1-May-2007


Page: 1 2 3

Related medicine news :

1. Studies show antidepressants not linked to birth defects
2. Studies show role of age, gender, race and weight on cancer risk and treatment
3. Studies highlight advances in diagnosis, medical therapy
4. Studies highlight real world use, safety of drug-eluting stents
5. Studies led by Rhode Island Hospital confirm safety and efficacy
6. Studies identify food sources of disease and drug resistance
7. Studies provide new evidence on risks associated with Cox-2 inhibitors and NSAIDs
8. Studies highlight need to monitor heart function in breast cancer patients
9. Studies examine physician disclosure of medical errors
10. Studies indicate medication can be an effective therapy for smoking cessation
11. Studies evaluating health effects of dental amalgam fillings in children confirm safety

Post Your Comments:
(Date:8/29/2015)... , ... August 30, 2015 , ... Rio Salado ... to serve as the college’s Vice President of Strategic Initiatives and Information Services. O’Shea, ... to help the college expand its reach and impact through innovative technologies and strategies. ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... support and protection against dribbled urine and sweat. "In order to prevent these ... , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support for a ...
(Date:8/29/2015)... Aliso Viejo, CA (PRWEB) , ... August 29, 2015 , ... ... Cut Pro X . Each preset contains 15 seconds of unique footage that users ... presets that rise, fall, zoom, attract and more. Users can customize color, brightness, scale, ...
(Date:8/28/2015)... ... ... Rio Salado College joined nine educational institutions in Washington D.C., July ... - Next Generation Learning Challenges 2015 Breakthrough Models Incubator funded by the Bill ... hosted by EDUCAUSE and NGLC, which is designed to bring leadership teams of ...
(Date:8/28/2015)... Los Angeles, CA (PRWEB) , ... August 28, 2015 , ... ... seemingly endless journey that local pizza maker Paul LaRocco has gone through to open ... the city approval and permitting process tends to take several months, but the current ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2
(Date:8/29/2015)... LONDRES, August 29, 2015 ... para los sistemas de imagen por Ultrasonidos   ... tiempos de examen rápidos y un flujo de trabajo ... diagnóstica en el proceso de detección de Cardiopatías   ... ha anunciado hoy el lanzamiento europeo de HeartModel ...
(Date:8/28/2015)... India , August 28, 2015 ... Biomarker Market by Tumor (Breast, Lung, Prostate) Type (Protein ... Application (Diagnostic, Drug Discovery, Prognostic) & Geography - Global ... Market is expected to reach around 17,689.0 Million USD ... forecast period of 2015 to 2020. ...
(Date:8/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/jq34zf/investigation ) ... on China,s Tobramycin Market, 2010-2019" report to their ... eye drop and ointment are the most common prescription ... caused by eye infection. Currently, dozens of enterprises in ... tobramycin, among which the Top 5 are s.a. Alcon- ...
Breaking Medicine Technology:Philips presenta HeartModel A.I en el Congreso ESC 2015 2Philips presenta HeartModel A.I en el Congreso ESC 2015 3Philips presenta HeartModel A.I en el Congreso ESC 2015 4Philips presenta HeartModel A.I en el Congreso ESC 2015 5Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 5Investigation Report on China's Tobramycin Market, 2015-2019 2
Cached News: